Chinook Therapeutics, Inc. (NASDAQ:KDNY) has received an average rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $31.71.
Several brokerages have recently weighed in on KDNY. Zacks Investment Research upgraded shares of Chinook Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 4th. Bloom Burton reissued a “buy” rating and set a $40.00 price target on shares of Chinook Therapeutics in a report on Monday, June 14th.
In other Chinook Therapeutics news, CEO Eric Dobmeier acquired 7,000 shares of the company’s stock in a transaction dated Wednesday, August 18th. The stock was acquired at an average cost of $11.74 per share, with a total value of $82,180.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Davis Jerel sold 850,000 shares of the firm’s stock in a transaction that occurred on Friday, August 27th. The stock was sold at an average price of $14.00, for a total transaction of $11,900,000.00. The disclosure for this sale can be found here. Company insiders own 29.75% of the company’s stock.
NASDAQ KDNY opened at $12.73 on Friday. Chinook Therapeutics has a 1 year low of $10.95 and a 1 year high of $21.68. The company has a market capitalization of $570.30 million, a PE ratio of -3.19 and a beta of 0.06. The company has a fifty day moving average of $13.26 and a two-hundred day moving average of $15.22.
Chinook Therapeutics (NASDAQ:KDNY) last announced its earnings results on Thursday, August 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. Chinook Therapeutics had a negative net margin of 2,885.36% and a negative return on equity of 52.69%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.25 million. As a group, sell-side analysts anticipate that Chinook Therapeutics will post -3.57 earnings per share for the current year.
Chinook Therapeutics Company Profile
Chinook Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Featured Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.